CA2477004A1 - Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances - Google Patents
Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances Download PDFInfo
- Publication number
- CA2477004A1 CA2477004A1 CA002477004A CA2477004A CA2477004A1 CA 2477004 A1 CA2477004 A1 CA 2477004A1 CA 002477004 A CA002477004 A CA 002477004A CA 2477004 A CA2477004 A CA 2477004A CA 2477004 A1 CA2477004 A1 CA 2477004A1
- Authority
- CA
- Canada
- Prior art keywords
- composition
- controlled substance
- active form
- chemical moiety
- controlled
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
The present invention provides methods for altering controlled substances in a manner that decreases their potential for abuse. The novel compounds may be combined in tablets with suitable excipients or formulated in solution for oral delivery. When delivered by the oral route the controlled substance is released in a time-dependent manner (sustained release) by acid hydrolysis and/or enzymatic cleavage. When administered by injection the controlled substance is released in a time-dependent manner (sustained release) by way of serum enzymes.
Claims (31)
1. A pharmaceutical composition comprising:
a controlled substance; and an amino acid or polypeptide covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive.
a controlled substance; and an amino acid or polypeptide covalently bound to said controlled substance in a manner that renders said controlled substance pharmacologically inactive.
2. The composition of claim 1, wherein said controlled substance is released in active form in the presence of acid present in the stomach or in the presence of enzymes present in the intestinal tract or blood serum.
3. The composition of claim 2, adapted for oral administration, wherein said controlled substance is released in active form in the presence of acid present in the stomach or in the presence of enzymes present in the intestinal tract.
4. The composition of claim 1, wherein said polypeptide comprises less than 70 amino acids.
5. The composition of claim 1, wherein said polypeptide comprises less than 50 amino acids.
6. The composition of claim 1, wherein said polypeptide comprises less than amino acids.
7. The composition of claim 1 wherein said chemical moiety is polyserine.
8. The composition of claim 1 wherein said chemical moiety is bound to said controlled substance by an ester or carbonate bond.
9. The composition of claim 1 wherein said controlled substance is codeine.
10. The composition of claim 1 wherein said controlled substance is fentanyl.
11. The composition of claim 1 wherein said controlled substance is hydrocodone.
12. The composition of claim 1 wherein said controlled substance is hydromorphone.
13. The composition of claim 1 wherein said controlled substance is levorphanol.
14. The composition of claim 1 wherein said controlled substance is methadone.
15. The composition of claim 1 wherein said controlled substance is morphine
16. The composition of claim 1 wherein said controlled substance is oxycodone.
17. The composition of claim 1 wherein said controlled substance is propoxyphene.
18. The composition of claim 1 wherein said controlled substance is sufentanyl.
19. The composition of claim 1 wherein said controlled substance is amphetamine.
20. The composition of claim 1 wherein said controlled substance is methylphenidate.
21. The composition of claim 1 wherein said chemical moiety is a polypeptide.
22. The composition of claim 1 wherein said chemical moiety is an amino acid.
23. The composition of claim 1 wherein said chemical moiety is a protein.
24. The composition of claim 3 that releases said controlled substance in a pharmacologically active form when administered to a human patient by the oral route.
25. The composition of claim 3 that is resistant to release of said controlled substance in a pharmacologically active form when administered by the intranasal route thus diminishing or preventing a euphoric effect.
26. The composition of claim 3 that is resistant to release of said controlled substance in a pharmacologically active form when administered by inhalation thus diminishing or preventing a euphoric effect.
27. A composition of claim 3 that is resistant to release of said controlled substance in a pharmacologically active form when administered by parenteral injection thus diminishing or preventing a euphoric effect.
28. A method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising orally administering the composition of claim 1 to said patient.
29. A method for delivering a controlled substance to a patient so as to obtain a therapeutic, but not a substantial euphoric effect, comprising parenterally administering the composition of claim 1 to said patient.
30. A composition of claim 1 wherein the said chemical moiety is an oligopeptide.
31. A composition of claim 30 wherein the said oligopeptide is specifically designed to be cleaved by intestinal enzymes.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2740256A CA2740256A1 (en) | 2002-02-22 | 2003-02-24 | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35836802P | 2002-02-22 | 2002-02-22 | |
US60/358,368 | 2002-02-22 | ||
US36208202P | 2002-03-07 | 2002-03-07 | |
US60/362,082 | 2002-03-07 | ||
PCT/US2003/005525 WO2003072046A2 (en) | 2002-02-22 | 2003-02-24 | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2740256A Division CA2740256A1 (en) | 2002-02-22 | 2003-02-24 | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2477004A1 true CA2477004A1 (en) | 2003-09-04 |
CA2477004C CA2477004C (en) | 2011-05-10 |
Family
ID=27767540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2477004A Expired - Fee Related CA2477004C (en) | 2002-02-22 | 2003-02-24 | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances |
Country Status (9)
Country | Link |
---|---|
US (1) | US7622441B2 (en) |
EP (2) | EP1531844B1 (en) |
JP (1) | JP4878732B2 (en) |
KR (1) | KR100822498B1 (en) |
AU (2) | AU2003219863C1 (en) |
CA (1) | CA2477004C (en) |
ES (1) | ES2500117T3 (en) |
IL (2) | IL163667A0 (en) |
WO (1) | WO2003072046A2 (en) |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
US20070060500A1 (en) * | 2000-08-22 | 2007-03-15 | New River Pharmaceuticals Inc. | Pharmaceutical compositions for prevention of overdose or abuse |
US20090306228A1 (en) * | 2000-11-14 | 2009-12-10 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US8394813B2 (en) * | 2000-11-14 | 2013-03-12 | Shire Llc | Active agent delivery systems and methods for protecting and administering active agents |
US20060014697A1 (en) * | 2001-08-22 | 2006-01-19 | Travis Mickle | Pharmaceutical compositions for prevention of overdose or abuse |
US7169752B2 (en) * | 2003-09-30 | 2007-01-30 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7375082B2 (en) * | 2002-02-22 | 2008-05-20 | Shire Llc | Abuse-resistant hydrocodone compounds |
US20070066537A1 (en) * | 2002-02-22 | 2007-03-22 | New River Pharmaceuticals Inc. | Compounds and compositions for prevention of overdose of oxycodone |
US7338939B2 (en) * | 2003-09-30 | 2008-03-04 | New River Pharmaceuticals Inc. | Abuse-resistant hydrocodone compounds |
US20040156844A1 (en) * | 2002-05-22 | 2004-08-12 | Curtis Wright | Tamper resistant oral dosage form |
US6913768B2 (en) * | 2002-09-24 | 2005-07-05 | Shire Laboratories, Inc. | Sustained release delivery of amphetamine salts |
US8133881B2 (en) | 2003-01-13 | 2012-03-13 | Shire Llc | Carbohydrate conjugates to prevent abuse of controlled substances |
KR20050098246A (en) * | 2003-01-13 | 2005-10-11 | 뉴 리버 파마슈티칼스, 인크. | Carbohydrate conjugates to prevent abuse of controlled substances |
DE602004024963D1 (en) * | 2003-03-13 | 2010-02-25 | Controlled Chemicals Inc | OXYCODON CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED ACTIVITY |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
KR101170840B1 (en) * | 2003-05-29 | 2012-08-03 | 샤이어 엘엘씨 | Abuse resistant amphetamine compounds |
EP1675555A4 (en) * | 2003-09-30 | 2011-03-09 | Shire Llc | Pharmaceutical compositions for prevention of overdose or abuse |
WO2005044236A1 (en) * | 2003-10-27 | 2005-05-19 | Control Delivery Systems, Inc. | Suspension delivery system for the sustained and controlled local release of pharmaceuticals |
JP2008519055A (en) * | 2004-11-08 | 2008-06-05 | シャイア エルエルシー | Synergistic effect of combined administration of mirtazapine and stimulant complex |
WO2006055729A1 (en) * | 2004-11-16 | 2006-05-26 | Transcutaneous Technologies Inc. | Iontophoretic device and method for administering immune response-enhancing agents and compositions |
JP2006296511A (en) * | 2005-04-15 | 2006-11-02 | Transcutaneous Technologies Inc | External preparation, method for applying external preparation, iontophoresis device, and transdermal patch |
AR057035A1 (en) * | 2005-05-25 | 2007-11-14 | Progenics Pharm Inc | SYNTHESIS OF (R) -N-METHYLNTREXONE, PHARMACEUTICAL COMPOSITIONS AND USES |
US20070135754A1 (en) * | 2005-09-30 | 2007-06-14 | Hidero Akiyama | Electrode assembly for iontophoresis for administering active agent enclosed in nanoparticle and iontophoresis device using the same |
US20070078375A1 (en) * | 2005-09-30 | 2007-04-05 | Transcutaneous Technologies Inc. | Iontophoretic delivery of active agents conjugated to nanoparticles |
JP2009509677A (en) * | 2005-09-30 | 2009-03-12 | Tti・エルビュー株式会社 | Iontophoretic delivery of vesicle encapsulated active substances |
WO2007041314A2 (en) * | 2005-09-30 | 2007-04-12 | Tti Ellebeau, Inc. | Transdermal drug delivery systems, devices, and methods employing novel pharmaceutical vehicles |
US7848801B2 (en) * | 2005-12-30 | 2010-12-07 | Tti Ellebeau, Inc. | Iontophoretic systems, devices, and methods of delivery of active agents to biological interface |
WO2007120864A2 (en) * | 2006-04-14 | 2007-10-25 | Shire Llc | Compositions and methods for enhancing analgesic potency of covalently bound compounds, attenuating its adverse side effects, and preventing their abuse |
SG172633A1 (en) | 2006-05-26 | 2011-07-28 | Pharmacofore Inc | Controlled release of phenolic opioids |
US20080207668A1 (en) * | 2006-10-06 | 2008-08-28 | New River Pharmaceuticals Inc. | Pharmaceutical compositions of hydromorphone for prevention of overdose or abuse |
PL2124556T3 (en) | 2006-10-09 | 2015-02-27 | Charleston Laboratories Inc | Pharmaceutical compositions |
US20080193514A1 (en) * | 2006-11-02 | 2008-08-14 | Transcu Ltd. | Compostions and methods for iontophoresis delivery of active ingredients through hair follicles |
AU2007333105A1 (en) * | 2006-12-11 | 2008-06-19 | Kempharm, Inc. | Non-standard amino acid conjugates of amphetamine and processes for making and using the same |
JPWO2008087803A1 (en) * | 2007-01-16 | 2010-05-06 | 国立大学法人北海道大学 | Liposome preparation for iontophoresis encapsulating antioxidant components |
EP2109465B1 (en) | 2007-02-08 | 2012-04-11 | Kempharm, Inc. | Polar hydrophilic prodrugs of amphetamine and other stimulants and processes for making and using the same |
US20110105381A2 (en) * | 2007-02-16 | 2011-05-05 | Pharmacofore, Inc. | Prodrugs of Peripheral Phenolic Opioid Antagonists |
RU2482841C2 (en) * | 2007-05-18 | 2013-05-27 | ТиТиАй Эллебо, Инк. | Devices for transdermal delivery, providing improved release of active substance through biological surface |
JP2010187707A (en) * | 2007-06-12 | 2010-09-02 | Hokkaido Univ | Liposome preparation for iontophoresis comprising insulin encapsulated therein |
ES2692437T3 (en) | 2007-08-13 | 2018-12-03 | Abuse Deterrent Pharmaceutical Llc | Abuse-resistant drugs, method of use and method of preparation |
US9023860B2 (en) | 2007-11-26 | 2015-05-05 | Signature Therapeutics, Inc. | Pro-drugs for controlled release of biologically active compounds |
EP2240022B1 (en) | 2008-01-09 | 2016-12-28 | Charleston Laboratories, Inc. | Bilayered tablets comprising oxycodone and promethazine |
TW201026347A (en) * | 2008-09-10 | 2010-07-16 | Transcu Ltd | Apparatus and method to dispense HPC-based viscous liquids into porous substrates, e. g., continuous web-based process |
ES2414856T3 (en) | 2008-12-12 | 2013-07-23 | Paladin Labs Inc. | Narcotic drug formulations with decreased addiction potential |
BRPI0923836A2 (en) | 2008-12-31 | 2015-07-21 | Upsher Smith Lab Inc | Opioid-containing oral pharmaceutical compositions and methods |
US10849981B2 (en) | 2009-07-02 | 2020-12-01 | KemPham, Inc. | Benzoic acid, benzoic acid derivatives and heteroaryl carboxylic acid conjugates of hydrocodone, prodrugs, methods of making and use thereof |
UA102916C2 (en) | 2009-07-02 | 2013-08-27 | Кемфарм, Інк. | Composition based on conjugates of hydrocodone with benzoic acid, benzoic acid or heteroaryl carboxylic acid derivatives, prodrugs and method for treatment of abuses |
US20120142720A1 (en) | 2009-07-02 | 2012-06-07 | Kempharm, Inc. | Phenylethanoic Acid, Phenylpropanoic Acid and Phenylpropenoic Acid Conjugates and Prodrugs of Hydrocodone, Methods of Making and Use Thereof |
WO2011006012A1 (en) | 2009-07-08 | 2011-01-13 | Charleston Laboratories Inc. | Pharmaceutical compositions |
EP2453900A1 (en) | 2009-07-17 | 2012-05-23 | Shire LLC | Novel carbamate amino acid and peptide prodrugs of opioids and uses thereof |
EP2477610A1 (en) | 2009-09-17 | 2012-07-25 | Upsher-Smith Laboratories, Inc. | A sustained-release product comprising a combination of a non-opioid amine and a non-steroidal anti -inflammatory drug |
WO2011133346A1 (en) * | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Peripheral opioid agonists and peripheral opioid antagonists |
US20110262355A1 (en) | 2010-04-21 | 2011-10-27 | Jenkins Thomas E | Compositions comprising enzyme-cleavable opioid prodrugs and inhibitors thereof |
WO2011133348A1 (en) | 2010-04-21 | 2011-10-27 | Pharmacofore, Inc. | Compositions comprising enzyme-cleavable amphetamine prodrugs and inhibitors thereof |
AU2012205733B2 (en) | 2011-01-11 | 2015-10-08 | Signature Therapeutics, Inc. | Compositions comprising enzyme-cleavable oxycodone prodrug |
RU2608305C2 (en) | 2011-03-09 | 2017-01-17 | Сигничер Терапьютикс, Инк. | Prodrugs of active substances with heterocyclic linkers |
WO2012122420A2 (en) | 2011-03-09 | 2012-09-13 | Pharmacofore, Inc. | Opioid prodrugs with heterocyclic linkers |
WO2014146093A2 (en) | 2013-03-15 | 2014-09-18 | Inspirion Delivery Technologies, Llc | Abuse deterrent compositions and methods of use |
EP3193873A4 (en) * | 2014-09-15 | 2018-05-30 | Inspirion Delivery Technologies, LLC | Orally administrable compositions and methods of deterring abuse by intranasal administration |
US10729685B2 (en) | 2014-09-15 | 2020-08-04 | Ohemo Life Sciences Inc. | Orally administrable compositions and methods of deterring abuse by intranasal administration |
BR112017011069A2 (en) | 2014-11-25 | 2018-07-10 | Kempharm Inc | benzoic acid, derivatives and benzoic acid and conjugates of oxycodone heteroaryl carboxylic acid |
US9987269B2 (en) | 2015-04-27 | 2018-06-05 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of oxymorphone and uses thereof |
US10449190B2 (en) | 2015-04-27 | 2019-10-22 | John K. Thottathil | Alpha-hydroxy carboxylic acid and derivatives and other GRAS-based prodrugs of opioids and uses thereof |
US10017519B2 (en) * | 2015-04-27 | 2018-07-10 | 3St Research Llc | Alpha-hydroxy carboxylic acid and derivatives and other GRAS based prodrugs of oxycodone and uses thereof |
US10226456B2 (en) | 2015-04-27 | 2019-03-12 | 3St Research Llc | Methods and compositions for preventing opioid abuse |
EP3423041A4 (en) | 2016-03-04 | 2019-09-11 | Charleston Laboratories, Inc. | Pharmaceutical compositions |
EP3595663A4 (en) * | 2017-03-17 | 2021-01-13 | Elysium Therapeutics, Inc. | Polysubunit opioid prodrugs resistant to overdose and abuse |
WO2019018638A1 (en) * | 2017-07-20 | 2019-01-24 | Suzhou Runxindatai Pharmaceutics Ltd Co. | Abuse-resistant long-acting release opioid prodrugs |
JP7284764B2 (en) | 2018-02-23 | 2023-05-31 | ロデス テクノロジーズ | Novel opioid compounds and uses thereof |
Family Cites Families (83)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2507631A (en) | 1944-01-19 | 1950-05-16 | Ciba Pharm Prod Inc | Pyridine and piperidine compounds and process of making same |
DE1493824A1 (en) * | 1964-01-27 | 1969-05-22 | Hoffmann La Roche | Process for the preparation of aminocarboxylic acid amides |
CH406567A (en) | 1964-02-10 | 1966-01-31 | Inventio Ag | Device for controlling the setpoint value during the deceleration process in elevators with speed-controlled drives |
GB1112347A (en) | 1965-08-20 | 1968-05-01 | Pierre Wirth | Salts of organic bases with n-carbamyl-l-glutamic acid |
US3846399A (en) * | 1969-04-10 | 1974-11-05 | Merck & Co Inc | Process for controlled stepwise synthesis of polypeptides |
US3975342A (en) * | 1972-05-15 | 1976-08-17 | Biological Developments, Inc. | Tyrosyl-class antigenic conjugates, their preparation and antibodies raised thereto |
US3884898A (en) * | 1972-08-18 | 1975-05-20 | Syva Co | Normorphine derivatives bonded to proteins |
US3843696A (en) * | 1972-09-05 | 1974-10-22 | Syva Co | Methadone analog compounds |
US3878187A (en) * | 1972-09-11 | 1975-04-15 | Syva Co | Polypeptide derivatives of amphetamine and analogs for immunoassays |
US3998799A (en) * | 1973-11-02 | 1976-12-21 | Interx Research Corporation | Novel, transient pro-drug forms of l-dopa |
US4040907A (en) * | 1974-06-20 | 1977-08-09 | Syva Company | Iodothyronine enzyme conjugates |
US4025501A (en) * | 1975-03-20 | 1977-05-24 | Syva Company | Polypeptide propoxyphene derivatives for immunoassay reagents |
GB1592552A (en) * | 1976-12-10 | 1981-07-08 | Inst Nat Sante Rech Med | Pseudopeptides used as medicaments |
US4356166A (en) * | 1978-12-08 | 1982-10-26 | University Of Utah | Time-release chemical delivery system |
US4399121A (en) * | 1981-11-04 | 1983-08-16 | Miles Laboratories, Inc. | Iodothyronine immunogens and antibodies |
US4427660A (en) * | 1982-03-03 | 1984-01-24 | Research Corporation | Formyl-methionyl chemotatic peptide antibiotic conjugates useful in treating infections |
HU185535B (en) * | 1982-05-25 | 1985-02-28 | Mta Koezponti Hivatala | Process for preparing new gonadoliberin derivatives |
US4457907A (en) * | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
US4650675A (en) * | 1983-08-18 | 1987-03-17 | The Children's Medical Center Corporation | Oligonucleotide conjugates |
EP0179023B1 (en) * | 1984-10-19 | 1991-01-23 | Battelle Memorial Institute | With micro-organisms degradable polypeptide, and its use for the progressive release of medicaments |
GB8500209D0 (en) | 1985-01-04 | 1985-02-13 | Ceskoslovenska Akademie Ved | Synthetic polymeric drugs |
US4863735A (en) * | 1985-02-19 | 1989-09-05 | Massachusetts Institute Of Technology | Biodegradable polymeric drug delivery system with adjuvant activity |
US4902505A (en) * | 1986-07-30 | 1990-02-20 | Alkermes | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
IN165717B (en) * | 1986-08-07 | 1989-12-23 | Battelle Memorial Institute | |
DK406686D0 (en) * | 1986-08-26 | 1986-08-26 | Hans Bundgaard | carboxylic acid derivatives |
US5169933A (en) * | 1988-08-15 | 1992-12-08 | Neorx Corporation | Covalently-linked complexes and methods for enhanced cytotoxicity and imaging |
US5026827A (en) * | 1988-09-02 | 1991-06-25 | Matsushita Electric Industrial Co., Ltd. | Amphetamine-protein complex as immunogen for obtaining antibodies specific to methamphetamine |
US4960790A (en) * | 1989-03-09 | 1990-10-02 | University Of Kansas | Derivatives of taxol, pharmaceutical compositions thereof and methods for the preparation thereof |
US5767227A (en) * | 1989-11-03 | 1998-06-16 | Lotus Biochemical Corp. | Iodothyronine polymers |
US5219564A (en) * | 1990-07-06 | 1993-06-15 | Enzon, Inc. | Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon |
DE69103503T2 (en) | 1990-09-28 | 1995-01-05 | Mercian Corp | Adriamycin derivatives. |
US5238714A (en) * | 1990-10-02 | 1993-08-24 | Board Of Regents, The University Of Texas System | Efficient microcapsule preparation and method of use |
US5811447A (en) * | 1993-01-28 | 1998-09-22 | Neorx Corporation | Therapeutic inhibitor of vascular smooth muscle cells |
CA2096495C (en) * | 1992-06-16 | 2002-07-09 | Kathy Palmer Ordonez | Dual analyte immunoassay |
GB9213077D0 (en) * | 1992-06-19 | 1992-08-05 | Erba Carlo Spa | Polymerbound taxol derivatives |
US5534496A (en) * | 1992-07-07 | 1996-07-09 | University Of Southern California | Methods and compositions to enhance epithelial drug transport |
GB9215780D0 (en) * | 1992-07-24 | 1992-09-09 | Univ London Pharmacy | Peptide compounds |
US6093391A (en) * | 1992-10-08 | 2000-07-25 | Supratek Pharma, Inc. | Peptide copolymer compositions |
IL107400A0 (en) | 1992-11-10 | 1994-01-25 | Cortech Inc | Bradykinin antagonists |
US5298410A (en) * | 1993-02-25 | 1994-03-29 | Sterling Winthrop Inc. | Lyophilized formulation of polyethylene oxide modified proteins with increased shelf-life |
US5891459A (en) * | 1993-06-11 | 1999-04-06 | The Board Of Trustees Of The Leland Stanford Junior University | Enhancement of vascular function by modulation of endogenous nitric oxide production or activity |
WO1995012604A1 (en) | 1993-11-05 | 1995-05-11 | Aktiebolaget Astra | Novel amino acid derivatives |
AU5825094A (en) | 1993-11-19 | 1995-06-06 | Astra Aktiebolag | Novel dipeptide derivatives |
GB9401891D0 (en) * | 1994-02-01 | 1994-03-30 | Boots Co Plc | Therapeutic agents |
US5847436A (en) * | 1994-03-18 | 1998-12-08 | Kabushiki Kaisha Tokai Rika Denki Seisakusho | Bipolar transistor having integrated thermistor shunt |
US5716614A (en) * | 1994-08-05 | 1998-02-10 | Molecular/Structural Biotechnologies, Inc. | Method for delivering active agents to mammalian brains in a complex with eicosapentaenoic acid or docosahexaenoic acid-conjugated polycationic carrier |
US5910569A (en) * | 1994-11-22 | 1999-06-08 | Lotus Biochemical Corporation | Iodothyronine polymers |
US5846743A (en) | 1995-02-22 | 1998-12-08 | Brigham And Women's Hospital, Inc. | Polyphoshoinositide binding peptides for intracellular drug delivery |
US5710256A (en) * | 1995-04-03 | 1998-01-20 | Biosite Diagnostics Incorporated | Methadone derivatives and protein and polypeptide methadone derivative conjugates and labels |
US5670477A (en) | 1995-04-20 | 1997-09-23 | Joseph F. Poduslo | Method to enhance permeability of the blood/brain blood/nerve bariers to therapeutic agents |
JP4256932B2 (en) * | 1995-06-07 | 2009-04-22 | ジョエル ケイ. スワデッシュ | Antigen processing cell target complex |
US5762909A (en) * | 1995-08-31 | 1998-06-09 | General Electric Company | Tumor targeting with polymeric molecules having extended conformation |
US5851536A (en) | 1995-11-22 | 1998-12-22 | University Of Washington | Therapeutic delivery using compounds self-assembled into high axial ratio microstructures |
US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
NZ332234A (en) * | 1996-03-12 | 2000-06-23 | Pg Txl Company Lp | Water soluble paclitaxel prodrugs formed by conjugating paclitaxel or docetaxel with a polyglutamic acid polymer and use for treating cancer |
GB9606975D0 (en) | 1996-04-02 | 1996-06-05 | Univ Birmingham | Anti-tumor agent |
US6030941A (en) * | 1996-05-01 | 2000-02-29 | Avi Biopharma, Inc. | Polymer composition for delivering substances in living organisms |
US5970477A (en) * | 1996-07-15 | 1999-10-19 | Bellsouth Intellectual Property Management Corporation | Method and system for allocating costs in a distributed computing network |
US5922695A (en) * | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
US5952294A (en) | 1996-07-31 | 1999-09-14 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Peptidyl prodrugs and methods of making and using the same |
US6013633A (en) * | 1997-08-07 | 2000-01-11 | University Of Cincinnati | Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
ATE251913T1 (en) * | 1997-05-21 | 2003-11-15 | Univ Leland Stanford Junior | COMPOSITION AND METHOD FOR DELAYING TRANSPORT THROUGH BIOLOGICAL MEMBRANES |
TW460478B (en) * | 1997-08-15 | 2001-10-21 | Chugai Pharmaceutical Co Ltd | Phenethylamine derivatives |
JP4465109B2 (en) * | 1997-12-17 | 2010-05-19 | エンゾン ファーマシューティカルズ,インコーポレーテッド | Polymer prodrugs of amino and hydroxyl containing bioactive agents |
UA53774C2 (en) * | 1997-12-22 | 2003-02-17 | Еро-Селтік, С.А. | Method of reducing abuse potential of an oral dosage form of opioid analgesic |
DE69929173T2 (en) | 1998-01-29 | 2006-08-24 | Monash University, Clayton | THERAPEUTIC COMPOUNDS |
US6048736A (en) * | 1998-04-29 | 2000-04-11 | Kosak; Kenneth M. | Cyclodextrin polymers for carrying and releasing drugs |
US6652864B1 (en) | 1998-12-21 | 2003-11-25 | Asilomar Pharmaceuticals, Inc. | Compounds for intracellular delivery of therapeutic moieties to nerve cells |
US7374779B2 (en) * | 1999-02-26 | 2008-05-20 | Lipocine, Inc. | Pharmaceutical formulations and systems for improved absorption and multistage release of active agents |
US6716452B1 (en) * | 2000-08-22 | 2004-04-06 | New River Pharmaceuticals Inc. | Active agent delivery systems and methods for protecting and administering active agents |
WO2000053233A1 (en) * | 1999-03-10 | 2000-09-14 | Lotus Biochemical Corporation | Use of protein conformation for the protection and release of chemical compounds |
US6309633B1 (en) * | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
EP1204406A2 (en) * | 1999-07-29 | 2002-05-15 | Roxane Laboratories, Inc. | Opioid sustained-released formulation |
HU229705B1 (en) * | 2000-02-08 | 2014-05-28 | Euro Celtique Sa | Tamper-resistant oral opioid agonist formulations |
US20020099013A1 (en) * | 2000-11-14 | 2002-07-25 | Thomas Piccariello | Active agent delivery systems and methods for protecting and administering active agents |
US6992076B2 (en) * | 2000-10-06 | 2006-01-31 | Xenoport, Inc. | Bile-acid derived compounds for providing sustained systemic concentrations of drugs after oral administration |
WO2002028882A1 (en) * | 2000-10-06 | 2002-04-11 | Xenoport, Inc. | Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism |
US20020098999A1 (en) | 2000-10-06 | 2002-07-25 | Gallop Mark A. | Compounds for sustained release of orally delivered drugs |
US6740641B2 (en) * | 2001-07-27 | 2004-05-25 | Euro-Celtique, S.A. | Sugar derivatives of hydromorphone, dihydromorphine and dihydromorphine, compositions thereof and uses for treating or preventing pain |
WO2003024480A2 (en) * | 2001-09-14 | 2003-03-27 | Cytos Biotechnology Ag | In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles |
DE602004024963D1 (en) * | 2003-03-13 | 2010-02-25 | Controlled Chemicals Inc | OXYCODON CONJUGATES WITH LOWER ABUSE POTENTIAL AND EXTENDED ACTIVITY |
-
2003
- 2003-02-24 ES ES03716144.5T patent/ES2500117T3/en not_active Expired - Lifetime
- 2003-02-24 CA CA2477004A patent/CA2477004C/en not_active Expired - Fee Related
- 2003-02-24 JP JP2003570793A patent/JP4878732B2/en not_active Expired - Fee Related
- 2003-02-24 EP EP03716144.5A patent/EP1531844B1/en not_active Expired - Lifetime
- 2003-02-24 AU AU2003219863A patent/AU2003219863C1/en not_active Ceased
- 2003-02-24 WO PCT/US2003/005525 patent/WO2003072046A2/en active Application Filing
- 2003-02-24 EP EP11151658A patent/EP2319540A1/en not_active Withdrawn
- 2003-02-24 KR KR1020047013136A patent/KR100822498B1/en active IP Right Grant
- 2003-02-24 IL IL16366703A patent/IL163667A0/en active IP Right Grant
-
2004
- 2004-08-22 IL IL163667A patent/IL163667A/en not_active IP Right Cessation
- 2004-08-23 US US10/923,257 patent/US7622441B2/en not_active Expired - Fee Related
-
2008
- 2008-10-16 AU AU2008229978A patent/AU2008229978B2/en not_active Withdrawn - After Issue
Also Published As
Publication number | Publication date |
---|---|
AU2003219863A1 (en) | 2003-09-09 |
EP1531844B1 (en) | 2014-08-20 |
AU2008229978B2 (en) | 2012-03-22 |
EP1531844A2 (en) | 2005-05-25 |
WO2003072046A2 (en) | 2003-09-04 |
IL163667A (en) | 2011-03-31 |
US7622441B2 (en) | 2009-11-24 |
KR100822498B1 (en) | 2008-04-16 |
EP2319540A1 (en) | 2011-05-11 |
ES2500117T3 (en) | 2014-09-30 |
KR20040095228A (en) | 2004-11-12 |
IL163667A0 (en) | 2005-12-18 |
CA2477004C (en) | 2011-05-10 |
EP1531844A4 (en) | 2007-06-13 |
AU2003219863C1 (en) | 2009-03-05 |
WO2003072046A3 (en) | 2005-03-10 |
US20050080012A1 (en) | 2005-04-14 |
JP4878732B2 (en) | 2012-02-15 |
JP2005524648A (en) | 2005-08-18 |
AU2003219863B2 (en) | 2008-07-31 |
AU2008229978A1 (en) | 2008-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2477004A1 (en) | Novel sustained release pharmaceutical compounds to prevent abuse of controlled substances | |
US20100144645A1 (en) | Compositions and methods for enhancing analgesic potency of covalently bound-compounds, attenuating its adverse side effects, and preventing their abuse | |
JP2005524648A5 (en) | ||
US20210196706A1 (en) | Systems and Methods for Treating an Opioid-Induced Adverse Pharmacodynamic Response | |
JP2004536811A (en) | Sustained release analgesic compounds | |
WO2003080022A3 (en) | Analgesics for nasal administration | |
CN101330903A (en) | Abuse resistant transmucosal drug delivery device | |
US11186585B2 (en) | Compositions and methods of enhancing opioid receptor engagement by opioid hexadienoates and optionally substituted hexadienoates | |
EP1594513B1 (en) | Carbohydrate conjugates to prevent abuse of controlled substances | |
CN100413533C (en) | Sustained release pharmaceutical compounds to prevent abuse of controlled substances | |
JP2022544564A (en) | Compositions and methods for improving opioid receptor binding with opioid hexadienoates and selectively substituted hexadienoates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKLA | Lapsed |
Effective date: 20210224 |